CASC3 and central nervous system cancer: Bortezomib (BTZ) loaded Dual NLCs can effectively deliver BTZ to glioma cells, resulting in the highest therapeutic efficiency through inducing apoptosis, prolonged survival rate and efficient anti-glioma behaviour [76].